Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M

Código QR

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M

Guardado en:

Detalles Bibliográficos
Autor principal:	Xiaoying Zhang
Formato:	article
Lenguaje:	EN
Publicado:	Georg Thieme Verlag KG 2021
Materias:	Genetics QH426-470 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/252b3ac718da4cfca5ef207a3cbd1f8d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
por: Yaning Yang, et al.
Publicado: (2021)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Yen-Hsiang Huang, et al.
Publicado: (2021)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Yen-Hsiang Huang, et al.
Publicado: (2021)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Motohiro Tamiya, et al.
Publicado: (2021)

Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
por: Haomin Zhang, et al.
Publicado: (2021)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Tereza Vaclova, et al.
Publicado: (2021)

Minimalistic mycoplasmas harbor different functional toxin-antitoxin systems.
por: Virginia Hill, et al.
Publicado: (2021)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko B, et al.
Publicado: (2017)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

EGFRAP encodes a new negative regulator of the EGFR acting in both normal and oncogenic EGFR/Ras-driven tissue morphogenesis.
por: Jennifer Soler Beatty, et al.
Publicado: (2021)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Yurong Wang, et al.
Publicado: (2021)

Dissecting the multi-omics atlas of the exosomes released by human lung adenocarcinoma stem-like cells
por: Hai-Tao Luo, et al.
Publicado: (2021)

Continuous requirement for the Clr4 complex but not RNAi for centromeric heterochromatin assembly in fission yeast harboring a disrupted RITS complex.
por: Sreenath Shanker, et al.
Publicado: (2010)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Ken Uchibori, et al.
Publicado: (2017)

Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
por: Sumitra Mohan, et al.
Publicado: (2014)

Prognostic Implications and Immune Infiltration Analysis of ALDOA in Lung Adenocarcinoma
por: Guojun Lu, et al.
Publicado: (2021)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Maurício Fernando Silva Almeida Ribeiro, et al.
Publicado: (2021)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
por: Junjie GU, et al.
Publicado: (2021)

Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma
por: Daniel J. Tan, et al.
Publicado: (2020)

SWI/SNF associates with nascent pre-mRNPs and regulates alternative pre-mRNA processing.
por: Anu Tyagi, et al.
Publicado: (2009)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
por: Rong Wang, et al.
Publicado: (2020)

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
por: Bin Zou, et al.
Publicado: (2017)

Plasma cholesterol-induced lesion networks activated before regression of early, mature, and advanced atherosclerosis.
por: Johan L M Björkegren, et al.
Publicado: (2014)

AKAP13 couples GPCR signaling to mTORC1 inhibition.
por: Shihai Zhang, et al.
Publicado: (2021)

RiboRid: A low cost, advanced, and ultra-efficient method to remove ribosomal RNA for bacterial transcriptomics.
por: Donghui Choe, et al.
Publicado: (2021)

Activation of the Arabidopsis thaliana immune system by combinations of common ACD6 alleles.
por: Marco Todesco, et al.
Publicado: (2014)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Chaido Sirinian, et al.
Publicado: (2021)

The H3.3K27M oncohistone antagonizes reprogramming in Drosophila.
por: Kami Ahmad, et al.
Publicado: (2021)

A novel actin mRNA splice variant regulates ACTG1 expression.
por: Meghan C Drummond, et al.
Publicado: (2013)

DNASE1L3 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma Based on Data Mining
por: Jianlin Chen, et al.
Publicado: (2021)

M-DATA: A statistical approach to jointly analyzing de novo mutations for multiple traits.
por: Yuhan Xie, et al.
Publicado: (2021)

M-DATA: A statistical approach to jointly analyzing de novo mutations for multiple traits
por: Yuhan Xie, et al.
Publicado: (2021)

A homozygous stop-gain variant in ARHGAP42 is associated with childhood interstitial lung disease, systemic hypertension, and immunological findings.
por: Qifei Li, et al.
Publicado: (2021)

Identification of the circRNA-miRNA-mRNA Regulatory Network in Bladder Cancer by Bioinformatics Analysis
por: Jiancheng Lv, et al.
Publicado: (2021)

Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD.
por: Nancy L Saccone, et al.
Publicado: (2010)

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
por: Jeng-Sen Tseng, et al.
Publicado: (2014)

A combination of H2A.Z and H4 acetylation recruits Brd2 to chromatin during transcriptional activation.
por: Ryan Draker, et al.
Publicado: (2012)

The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma.
por: Irena Bočkaj, et al.
Publicado: (2021)

The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma
por: Irena Bočkaj, et al.
Publicado: (2021)